A Binded, Randomised, Controlled Cross-over Trial to Assess the Safety and Efficacy of Mucosal Covid-19 and Influenza Vaccines
Latest Information Update: 09 Aug 2024
At a glance
- Drugs COVAX 19 (Primary) ; Influenza A virus vaccine-H5N1 (Primary)
- Indications COVID 2019 infections; Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Vaxine
Most Recent Events
- 07 Aug 2024 Planned End Date changed from 21 Apr 2025 to 31 Dec 2025.
- 07 Aug 2024 Status changed from not yet recruiting to recruiting.
- 15 Apr 2024 New trial record